In May 2026, Akari reported significant preclinical findings for its lead cancer treatment AKTX-101, which demonstrated effective tumor-killing synergy when used with KRAS inhibitors in pancreatic cancer models. The company completed a PIPE in June 2026 and received approximately $8.3 million in total capital during Q2 2026, providing runway to advance clinical development and demonstrate proof-of-concept in Phase 1 trials.
Cyborg Score Rationale
Akari demonstrates promising preclinical data and a differentiated payload platform, but faces significant challenges as a micro-cap with limited cash runway and early-stage clinical development. Stock volatility and financing dependence pose execution risks, though the novel mechanism and positive data signals offer upside potential.
Top Insights
Lead candidate AKTX-101 demonstrated synergistic cytotoxic activity with KRAS inhibitors in pancreatic cancer models, potentially expanding addressable market in KRAS-driven cancers
Proprietary PH1 payload represents a differentiated mechanism targeting RNA splicing, distinct from conventional ADC payloads
Recent capital raise of $8.3 million in Q2 2026 funds Phase 1 first-in-human trial initiation for AKTX-101, a critical value inflection point
Micro-cap status ($5.77M market cap as of May 2026) with high stock volatility creates both execution risk and potential upside leverage
Named Competitors
Trop2-directed ADCs — Established ADC developers with approved Trop2 therapeutics
KRAS-targeting therapies — KRAS inhibitor developers and ADC innovators
Genmab — ADC developer with approved Trop2 and HER2 antibody-drug conjugates for oncology
Daiichi Sankyo — Leading ADC developer with approved HER2-targeted ADCs and next-generation payload technology
Astellas Pharma — Oncology-focused company developing ADC therapies and immunotherapies
Biotheranostics/BioModa — ADC technology developer focusing on novel payload and targeting mechanisms
Recent Developments
(May 2026) Reported preclinical data showing AKTX-101 synergy with KRAS inhibitors in pancreatic cancer models; stock surged 120%+ in after-hours trading
(May 2026) Received $2.8 million from warrant exercises by PIPE investors
(June 2026) Completed $5.5 million PIPE financing; combined with warrant proceeds totaled $8.3 million in Q2 2026 capital
(July 2026) Filed registration statement with SEC for securities offering
Open the full interactive Akari Therapeutics Plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.